This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Merck's (MRK) Keytruda Gets CHMP Nod for Expanded Melanoma Use
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer
by Zacks Equity Research
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates
by Zacks Equity Research
Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.
Bristol Myers (BMY) Phase III CheckMate -901 Study Disappoints
by Zacks Equity Research
Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor
by Zacks Equity Research
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss Wider
by Zacks Equity Research
Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023. BHVN also reports wider-than-expected Q1 loss.
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus
by Zacks Equity Research
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track
by Zacks Equity Research
Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.
Mirati (MRTX) Q1 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News
by Zacks Equity Research
Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
by Zacks Equity Research
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Pfizer (PFE) Q1 Earnings & Sales Miss Estimates, Stock Down
by Zacks Equity Research
Pfizer (PFE) misses estimates for Q1 earnings and sales. It did not raise its sales guidance for 2022. Stock declines.
How Will Pfizer's (PFE) Key Drugs Perform in Q1 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 products are likely to have driven sales in the first quarter.
Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down
by Zacks Equity Research
Bristol-Myers (BMY) earnings beat estimates in the first quarter of 2022. Sales jump year over year on the back of Eliquis and new products.
Core PCE Inflation at a 40-Year High in March
by Zacks Equity Research
Core PCE Inflation at a 40-Year High in March.
PCE +6.6%, Another 40-Year High; XOM, CL, BMY Report
by Mark Vickery
Inflation was clear and present in March, but a large chunk of it was due to food and energy prices.
Bristol Myers Squibb (BMY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 2.08% and 3.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN
by Zacks Equity Research
Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.
Why Bristol-Myers (BMY) Might Surprise This Earnings Season
by Zacks Equity Research
Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.